ABC=advanced breast cancer;  BC=breast cancer; BRCA=breast cancer susceptibility gene; gBRCA=germline breast cancer susceptibility gene; gBRCAm=germline breast cancer susceptibility gene mutation; HER2-=human epidermal growth factor receptor 2 negative; HR+=hormone receptor-positive; mBC=metastatic breast cancer; NCCN=National Comprehensive Cancer Network; TNBC=triple-negative breast cancer.

*According to a real-world analysis of gBRCA1/2 testing among 407 HER2- ABC patients in the US receiving treatment between 2019 and 2020.

References: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer. V.4.2022. June 21, 2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed June 29, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 2. Mahtani R, Niyazov A, Lewis K, et al. Real-world study of BRCA1/2 mutation (BRCA1/2mut) testing among adult patients (pts) with HER2- advanced breast cancer (ABC) in the US. J Natl Compr Canc Netw. 2021;19(3.5). https://doi.org/10.6004/jnccn.2020.7760. Referenced with permission from the National Comprehensive Cancer Network, Inc. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved.